Literature DB >> 21547527

Treatment of chronic migraine headache with onabotulinumtoxinA.

Robert Gerwin1.   

Abstract

Chronic migraine headache remains an exceedingly difficult entity to manage. Treatment of chronic migraine headache with onabotulinumtoxinA has recently been shown to be effective in reducing the severity and frequency of chronic migraine headache, in the PREEMPT trials, a landmark achievement. However, the studies use a primarily fixed dose and site approach to treatment, allowing some individualized injections. However, the authors do not address the issue of myofascial trigger points as potential triggers of migraine that could be inactivated using onabotulinumtoxinA, despite several studies that support the role of myofascial trigger points in initiating some migraine headaches.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21547527     DOI: 10.1007/s11916-011-0202-6

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN: 1534-3081


  9 in total

1.  Regulation of calcitonin gene-related peptide secretion from trigeminal nerve cells by botulinum toxin type A: implications for migraine therapy.

Authors:  Paul L Durham; Ryan Cady; Roger Cady
Journal:  Headache       Date:  2004-01       Impact factor: 5.887

2.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial.

Authors:  H C Diener; D W Dodick; S K Aurora; C C Turkel; R E DeGryse; R B Lipton; S D Silberstein; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

3.  OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial.

Authors:  S K Aurora; D W Dodick; C C Turkel; R E DeGryse; S D Silberstein; R B Lipton; H C Diener; M F Brin
Journal:  Cephalalgia       Date:  2010-03-17       Impact factor: 6.292

Review 4.  Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A.

Authors:  K R Aoki
Journal:  Neurotoxicology       Date:  2005-07-05       Impact factor: 4.294

5.  OnabotulinumtoxinA for treatment of chronic migraine: pooled results from the double-blind, randomized, placebo-controlled phases of the PREEMPT clinical program.

Authors:  David W Dodick; Catherine C Turkel; Ronald E DeGryse; Sheena K Aurora; Stephen D Silberstein; Richard B Lipton; Hans-Christoph Diener; Mitchell F Brin
Journal:  Headache       Date:  2010-05-07       Impact factor: 5.887

6.  Prevalence and significance of muscle tenderness during common migraine attacks.

Authors:  P Tfelt-Hansen; I Lous; J Olesen
Journal:  Headache       Date:  1981-03       Impact factor: 5.887

7.  Method of injection of onabotulinumtoxinA for chronic migraine: a safe, well-tolerated, and effective treatment paradigm based on the PREEMPT clinical program.

Authors:  Andrew Blumenfeld; Stephen D Silberstein; David W Dodick; Sheena K Aurora; Catherine C Turkel; William J Binder
Journal:  Headache       Date:  2010-10       Impact factor: 5.887

8.  Synaptobrevin I mediates exocytosis of CGRP from sensory neurons and inhibition by botulinum toxins reflects their anti-nociceptive potential.

Authors:  Jianghui Meng; Jiafu Wang; Gary Lawrence; J Oliver Dolly
Journal:  J Cell Sci       Date:  2007-07-31       Impact factor: 5.285

9.  Contribution of myofascial trigger points to migraine symptoms.

Authors:  Maria Adele Giamberardino; Emmanuele Tafuri; Antonella Savini; Alessandra Fabrizio; Giannapia Affaitati; Rosanna Lerza; Livio Di Ianni; Domenico Lapenna; Andrea Mezzetti
Journal:  J Pain       Date:  2007-08-09       Impact factor: 5.820

  9 in total
  6 in total

Review 1.  Botulinum Toxin in Migraine Treatment.

Authors:  Elif Ilgaz Aydinlar; Pınar Yalinay Dikmen; Ayşe Sağduyu Kocaman
Journal:  Noro Psikiyatr Ars       Date:  2013-08-01       Impact factor: 1.339

Review 2.  Chronic migraine plus medication overuse headache: two entities or not?

Authors:  Andrea Negro; Paolo Martelletti
Journal:  J Headache Pain       Date:  2011-09-22       Impact factor: 7.277

3.  Critical analysis of the use of onabotulinumtoxinA (botulinum toxin type A) in migraine.

Authors:  Carrie E Robertson; Ivan Garza
Journal:  Neuropsychiatr Dis Treat       Date:  2012-01-13       Impact factor: 2.570

4.  Topographic Relationship between the Supratrochlear Nerve and Corrugator Supercilii Muscle--Can This Anatomical Knowledge Improve the Response to Botulinum Toxin Injections in Chronic Migraine?

Authors:  Hyung-Jin Lee; Kwang-Seok Choi; Sung-Yoon Won; Prawit Apinuntrum; Kyung-Seok Hu; Seong-Taek Kim; Tanvaa Tansatit; Hee-Jin Kim
Journal:  Toxins (Basel)       Date:  2015-07-17       Impact factor: 4.546

5.  OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study.

Authors:  Danièle Ranoux; Gaelle Martiné; Gaëlle Espagne-Dubreuilh; Marlène Amilhaud-Bordier; François Caire; Laurent Magy
Journal:  J Headache Pain       Date:  2017-07-21       Impact factor: 7.277

Review 6.  Therapeutic use of botulinum toxin in pain treatment.

Authors:  Raj Kumar
Journal:  Neuronal Signal       Date:  2018-08-31
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.